Corporate News 11-Feb-22
Alkem signs license agreement with Harvard University's Office of Technology Development
Alkem Laboratories has signed a license agreement with Harvard University's Office of Technology Development (OTD) enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease. The license grants Alkem commercialization rights in the United States and India.
Previous News
Alkem Laboratories
( Results - Analysis 30-May-24 10:39 )
Alkem Laboratories fixes record date for final dividend
( Market Beat - Reports 29-May-24 14:10 )
Alkem Lab reports cyber incident
( Hot Pursuit - 13-Jan-24 15:40 )
Alkem Laboratories Ltd soars 1.34%, rises for third straight session
( Hot Pursuit - 05-Jul-24 13:05 )
Alkem Lab reports cyber incident
( Hot Pursuit - 15-Jan-24 10:22 )
Alkem Laboratories Ltd gains for fifth session
( Hot Pursuit - 08-Feb-24 13:00 )
Alkem Laboratories to hold board meeting
( Corporate News - 03-Feb-24 11:30 )
Alkem Laboratories announces cessation of director
( Corporate News - 18-Aug-22 14:07 )
Alkem Lab Indore plant gets USFDA observation
( Hot Pursuit - 08-Jul-22 09:18 )
Alkem Laboratories Ltd rises for third straight session
( Hot Pursuit - 24-Jul-23 13:05 )
Alkem Laboratories Ltd up for five straight sessions
( Hot Pursuit - 10-Feb-23 13:00 )
Other Stories
Vardhan Capital & Finance schedules AGM
06-Jul-24 17:34
Automotive Axles schedules AGM
06-Jul-24 17:34
Maruti Infrastructure to conduct AGM
06-Jul-24 17:34
Torrent Power schedules AGM
06-Jul-24 17:34
Raghav Productivity Enhancers to hold AGM
06-Jul-24 17:34
Berger Paints India schedules AGM
06-Jul-24 17:33
Walpar Nutritions to conduct AGM
06-Jul-24 17:33
Weizmann AGM scheduled
06-Jul-24 17:33
Gretex Industries schedules AGM
06-Jul-24 17:33
Karma Energy schedules AGM
06-Jul-24 17:33
Back
Top
